323948
Genetic variants in the PDLIM5 gene are associated with alcohol dependence and cancer
Methods:This study examined 72 SNPs in the SAGE sample with 1,066 AD cases and 1,278 controls and 47 SNPs in the Marshfield sample with 1,442 cancer cases (any diagnosed cancer omitting minor skin cancer) and 2,112 non-cancer controls. Logistic regression analysis was performed using PLINK software, adjusted for age and sex.
Results: 16 SNPs were associated with the AD (P<0.01) where rs1048627 showed the strongest signal (P = 5.53 x 10-4). Interesting, 3 of the 16 SNPs also showed associations with cancer (rs6532496, rs7690296, and rs951613 with P = 0.00102, 0.00198, and 0.00138 for AD and P = 0.0214, 0.0475, and 0.0363 for cancer, respectively). Furthermore, the A-C haplotype from rs11732687 and rs11724023 and the T-A haplotype from rs11724023 and rs7690296 revealed significant associations with AD (P = 5.65 x 10-4 and 6.76 x 10-4, respectively).
Conclusion: The present study provides evidence of several genetic variants within PDLIM5 gene influencing the AD and cancer and will serve as a resource for replication in other populations.
Learning Areas:
Biostatistics, economicsChronic disease management and prevention
Epidemiology
Public health or related research
Learning Objectives:
Discuss the association between genetic variants in the PDLIM5 gene and alcohol dependance (AD)
List at least 3 alleles within the PDLIM5 gene associated with AD and cancer.
Discuss implications of finding for future research.
Keyword(s): Alcohol Use, Genetics
Qualified on the content I am responsible for because: I am a co-author of the research paper, and I have fully participated in the study. I am a first author and I have approval of other authors to present. I have previously co-authored three published papers in genetics. I have also presented in several scientific conferences. As a DrPH (Epidemiology) student, I have adequate knowledge in the field of public health which qualifies me to present.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.